Privia Health Group, Inc.

Valuation Analysis

About the Company

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platfo

Privia Health Group, Inc. Stock at a Glance

Privia Health Group, Inc. (PRVA) is currently trading at $23.43 with a market capitalization of $3B. The trailing P/E ratio stands at 137.82x, with a forward P/E of 21.35x. The 52-week range spans from $18.77 to $26.51; the current price is 11.6% below the yearly high. Year-over-year revenue growth stands at +25.8%. The net profit margin stands at 0.97%.

💰 Dividend

Privia Health Group, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

19 analysts rate Privia Health Group, Inc. (PRVA) on consensus: Strong Buy. The average price target is $31.42, implying +34.11% from the current price. Analyst price targets range from $24.00 to $40.00.

Privia Health Group, Inc.: The Investment Case in Detail

Privia Health Group, Inc. (PRVA) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 25.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Strong Buy with an average price target implying roughly 34.11% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

With a net margin of just 0.97%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The EV/EBITDA multiple of 54.37x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The forward P/E of 21.35x is meaningfully below the trailing 137.82x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 34.11% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

Related Stocks in the Same Sector

Where can I buy Privia Health Group, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.